- Home
- NKX vs PHAR Comparison
NKX vs PHAR Comparison
Compare NKX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKX
- PHAR
- Stock Information
- Founded
- NKX 2002
- PHAR 1988
- Country
- NKX United States
- PHAR Netherlands
- Employees
- NKX N/A
- PHAR N/A
- Industry
- NKX Finance/Investors Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NKX Finance
- PHAR Health Care
- Exchange
- NKX Nasdaq
- PHAR Nasdaq
- Market Cap
- NKX 549.4M
- PHAR 718.1M
- IPO Year
- NKX N/A
- PHAR N/A
- Fundamental
- Price
- NKX $11.78
- PHAR $10.27
- Analyst Decision
- NKX
- PHAR Strong Buy
- Analyst Count
- NKX 0
- PHAR 3
- Target Price
- NKX N/A
- PHAR $30.00
- AVG Volume (30 Days)
- NKX 109.3K
- PHAR 4.3K
- Earning Date
- NKX 01-01-0001
- PHAR 07-31-2025
- Dividend Yield
- NKX 4.37%
- PHAR N/A
- EPS Growth
- NKX N/A
- PHAR N/A
- EPS
- NKX N/A
- PHAR N/A
- Revenue
- NKX N/A
- PHAR $320,708,000.00
- Revenue This Year
- NKX N/A
- PHAR $13.31
- Revenue Next Year
- NKX N/A
- PHAR $7.68
- P/E Ratio
- NKX N/A
- PHAR N/A
- Revenue Growth
- NKX N/A
- PHAR 24.13
- 52 Week Low
- NKX $9.78
- PHAR $6.65
- 52 Week High
- NKX $12.00
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- NKX 54.52
- PHAR 48.21
- Support Level
- NKX $11.68
- PHAR $10.46
- Resistance Level
- NKX $11.82
- PHAR $11.49
- Average True Range (ATR)
- NKX 0.09
- PHAR 0.37
- MACD
- NKX 0.05
- PHAR -0.12
- Stochastic Oscillator
- NKX 84.21
- PHAR 27.62
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.